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In Europe, allergen extracts for sublingual 
immunotherapy (SLIT) are currently marketed by several 
manufacturers, thus the administration schedules and 
amount of allergens are quite variable in the different 
products. However, almost all the SLIT vaccines 
commercialized in Europe are standardized biologically 
or immunologically (1). The standardization methods 
are still largely based on in-house references, thus the 
extracts are labeled in units that differ from manufacturer 
to manufacturer. Some of the most used labeling units are: 
Allergen Units (AU), Index of Reactivity (IR), Biological 
Units (BU), Standard Units (STU). On the other hand, 
during the last few years the availability of the content 
in micrograms of the major allergens have represented 
a significant improvement, since this allows to roughly 
compare the different therapeutic regimens. In general, 
the dose of allergen given in a SLIT course is 5-300 times 
higher (again, according to the manufacturer) than in 
the correspondent subcutaneous immunotherapy (SCIT) 
so that the term high-dose SLIT is somewhere used to 
indicate this treatment (2).
The allergen extracts for SLIT are available in two 
main pharmaceutical forms:  a) solutions to be delivered 
by drop-counters, pre-dosed actuators (mini-pumps) or 
disposable single-dose vials; b) tablets with appropriate 
composition that allows a slow dissolution in the mouth in 
contact with oral mucosa. 
Concerning the US market, the American Medical 
Association’s Current Procedural Terminology 
2005 manual defines immunotherapy as “parenteral 
administration of allergenic extracts as antigens at 
periodic intervals” (3), therefore there are no FDA-
licensed products for SLIT in the United States. 
PRACTICAL ADMINISTRATION
The allergen extract, in solution or tablets, is usually 
administered in the morning before breakfast. The drops 
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friendly and convenient to manage. A randomized trial 
directly compared the safety of the traditional updosing 
regimen with the no-updosing in 135 patients and found 
no difference in the rate and type of adverse events with 
the two different approach (19). There was indeed a 
single report of anaphylaxis with an ultra-rush updosing 
with latex extract (20), therefore, caution should be taken 
during the induction phase with this allergen. 
The maintenance dose is generally the same for all 
patients and it is identified by the manufacturer, based on 
clinical results. The use of the same dose for all patients 
is justified by the fact that, differently from subcutaneous 
immunotherapy, also the administration of very high 
amounts of allergens does not provoke severe side effects. 
In one dose-finding study, one of the groups of patients 
received an amount of 1,000,000 Standardized  Quality 
Units per day, which correspond to 200 mcg of Phl p 5 
allergen (21). It was observed a certain dose-dependency 
of side effects, but even with the higher amount of 
allergen, the side effects were mostly local (oral itching/
swelling) and mild or moderate. The same results were 
reported also in patients suffering from asthma (22). Thus 
far, we do not know which is the dose that invariably 
provokes severe side effects, and this dose is conceivably 
much higher than the doses usually administered. 
The maintenance dose can be administered at time 
intervals that are variable among manufacturers. For 
instance, once daily (23), on alternate days (24), or once 
weekly regimens (25) have been proposed. Nowadays, 
the general trend is to simplify the regimen by giving 
the maintenance dose once daily, as done with almost all 
drugs. 
CRITERIA FOR STARTING AND STOPPING
SLIT can be administered either pre-co-seasonally 
(stop at the end of the season) or continuously. Pre-co-
seasonal schedules are commonly used for pollen allergy. 
In this case the treatment starts 2-3 months before the 
expected pollen season. In the pre-co-seasonal regimen, 
no dose reduction during the pollen season is usually 
applied. On the other hand, for nearly-perennial or 
perennial allergens, a continuous treatment is preferred. A 
recent study evaluated in patients allergic to dust mites the 
possibility to use a SLIT schedule with intermittent (i.e. 
2-month treatment alternating with 2-month suspension) 
administration of the mite extract, with comparable safety 
in respect to the continuous daily  administration (26). 
There is no published randomized controlled study on 
the optimal duration of a SLIT treatment, although long 
lasting clinical effects were reported with a 4-5 year course 
of treatment both in children (27) and adults (28). Since 
these evidences are insufficient, the recommendation for 
or tablets are kept under the tongue for 1-2 minutes and 
then swallowed (sublingual-swallow method). In some 
studies the allergen was kept under the tongue and then 
spat out and this technique is called sublingual-spit 
(4,5). Considering pharmacokinetics studies performed 
with radio-labeled allergens (6), it was found that, after 
spitting, a relevant amount of the allergen remains in 
the mouth. According to this observation and based on 
practical considerations of convenience and simplicity, the 
sublingual-swallow method is now considered the most 
appropriate and, therefore, is universally used in clinical 
trials and practice. The acronym SLIT, unless otherwise 
stated, indicates the sublingual-swallow modality. 
In the last years there was a renewed interest in the 
use of tablets and recent large trials were all performed 
with this preparation (7,8). Tablets are simpler to take 
than solutions, and their time of dissolution in the mouth 
can be fixed by an adequate formulation, but they cannot 
be divided. Taking into account the advantages and the 
possible disadvantages it is likely that soluble tablets will 
be in the future the most suitable way of administration.
In Europe, immunotherapy in general is prescribed for 
one or few allergens, and mixtures are less used than in the 
USA, although there is no immunological contraindication 
to give multiple allergens also with SLIT. A recent study 
has shown that SLIT treatment with a mixture of grass 
and birch was more effective than the single allergens 
alone (9). On the other hand, the co-administration of 
numerous extracts mixed together, in the case of adverse 
events, makes difficult the identification of the responsible 
extract. In addition, two cases of anaphylaxis recently 
described were provoked by heterogeneous mixtures of 
more than four different allergens given together (10,11). 
ADMINISTRATION REGIMENS  
SLIT traditionally involves a build-up or updosing 
phase (with gradually increasing doses) and a maintenance 
phase with the top dose (12). The build-up phase has 
usually the duration of  4-6 weeks. The extract is therefore 
prepared in separate vials (or in separate blisters of tablets) 
at different and increasing concentrations. The patient 
must start with the lowest concentration and gradually 
increase, using the different dosage preparations, until 
the maintenance dose is reached. Rush and ultra-rush 
inductions have been proposed, based on the safety 
profile of SLIT that is very favorable, also in children 
under the age of 5 years (13-14). Ultra-rush schemes 
with a build-up shorter than 2 hours has been reported in 
adults (15) and children (16-17), with favorable results. 
For these reasons it has been suggested that a an updosing 
phase maybe even not necessary (18). The no-updosing 
approach would result in a treatment that is more patient-
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the duration of SLIT must necessarily derive from the SCIT 
experience as reported in consensus documents (29-30). 
This implies that a SLIT course should be continued for 3 
to 5 years to expect log lasting efficacy, but discontinued 
if there is no benefit after 2 years of treatment. 
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